Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIN816 in sepsis-associated acute kidney injury (phase 2b dose-finding)
jRCT2071240059Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of TIN-816 in acute kidney failure (AKF) and sepsis-associated acute kidney injury (S-AKI) (4 arms), sponsored by Novartis. Primary endpoint: Average of area under the time-corrected creatinine clearance curve (AUC1-8). Started Nov 2024; status: active, not recruiting.
02
Drugs
TIN-816
03
Conditions
acute kidney failure (AKF)sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on jRCT2071240059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240059.